Combination and sequential treatment in women with postmenopausal osteoporosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination and sequential treatment in women with postmenopausal osteoporosis
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 4, Pages 477-490
Publisher
Informa UK Limited
Online
2020-01-29
DOI
10.1080/14656566.2020.1717468
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use
- (2019) Houchen Lyu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
- (2019) Benjamin Z Leder et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone Mineral Density After Transitioning From Denosumab to Alendronate
- (2019) David Kendler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT
- (2019) Sabashini K Ramchand et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial
- (2019) Joy N Tsai et al. Lancet Diabetes & Endocrinology
- Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
- (2018) Anne M. Horne et al. CALCIFIED TISSUE INTERNATIONAL
- THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
- (2018) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- (2018) Henry G Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
- (2018) E Michael Lewiecki et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis
- (2017) J. Y. Reginster et al. EXPERT OPINION ON PHARMACOTHERAPY
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis
- (2017) Felicia Cosman et al. MAYO CLINIC PROCEEDINGS
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- (2017) T. Lehmann et al. OSTEOPOROSIS INTERNATIONAL
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
- (2016) Paul D. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
- (2016) Kosuke Ebina et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
- (2016) Robert A Adler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
- (2016) P. D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
- (2016) M. Kamimura et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers
- (2015) Athanasios D. Anastasilakis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
- (2014) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy
- (2014) B. Hofstetter et al. OSTEOPOROSIS INTERNATIONAL
- Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches
- (2014) Felicia Cosman Current Osteoporosis Reports
- Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
- (2013) Yanfei L. Ma et al. BONE
- Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
- (2013) C. Roux et al. BONE
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
- (2013) Elizabeth Shane et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
- (2013) Joy N Tsai et al. LANCET
- Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy
- (2013) Chris Recknor et al. OBSTETRICS AND GYNECOLOGY
- Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density
- (2012) Christian Muschitz et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
- (2012) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Six Months of Parathyroid Hormone (1–84) Administered ConcurrentlyVersusSequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial
- (2012) Anne L. Schafer et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bisphosphonates for Osteoporosis — Where Do We Go from Here?
- (2012) Marcea Whitaker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate
- (2010) Barbara M Misof et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
- (2010) Elizabeth Shane et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
- (2010) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
- (2010) Joel S. Finkelstein et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
- (2010) J. J. Stepan et al. OSTEOPOROSIS INTERNATIONAL
- Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body
- (2009) Yan Chevalier et al. BONE
- Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate*
- (2009) Harald Dobnig et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
- (2009) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
- (2009) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
- (2008) René Rizzoli et al. BONE
- Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study*
- (2008) Helmut Minne et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment
- (2008) Barbara M Obermayer-Pietsch et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)*
- (2008) Richard Eastell et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
- (2008) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
- (2007) Steven Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started